论文部分内容阅读
目的:恩替卡韦(ETV)治疗HBeAg阳性慢性乙型肝炎（CHB）48周不完全病毒学应答(PVR)比例越来越高，此时调整治疗策略会给部分患者带来临床不良结局的风险。采用治疗前及治疗后24周病毒学和血清学指标，预测HBeAg阳性CHB患者应用ETV治疗48周PVR，指导临床早期调整治疗方案。方法:入组患者：2018年1月起开始在中国医科大学附属盛京医院感染科诊断的HBeAg阳性CHB初治患者，口服ETV单药治疗。根据48周HBV DNA检测结果进行分组，其中HBV DNA 2.205 log n 10 IU/ml (n OR = 43.197，95% n CI：6.858～272.069，n P 2 logn 10的患者继续治疗至48周均不能获得CVR，建议此时应该调整治疗策略。n “,”Objective:To study the virological and serological indicators before treatment and 24 weeks after treatment to predict the partial virological response (PVR) of 48-week entecavir (ETV) treatment, and formulate early clinical adjustment treatment plans for HBeAg-positive CHB patients.Methods:HBeAg-positive CHB-na?ve patients diagnosed in the Department of Infectious Diseases, Shengjing Hospital, China Medical University, who were treated with oral ETV monotherapy from January 2018 were enrolled. The groups were divided according to the test results of HBV DNA at 48 weeks. Among them, HBV DNA 2.205 log n 10 IU / ml (n OR = 43.197, 95% n CI: 6.858 ~ 272.069, n P 2 log n 10 at 24 weeks of treatment must wait 48 weeks to obtain CVR, so it is recommended that treatment strategies should be adjusted at this time.n